Exact group sequential designs for two-arm experiments with Poisson distributed outcome variables

Abstract We describe and compare two methods for the group sequential design of two-arm experiments with Poisson distributed data, which are based on a normal approximation and exact calculations respectively. A framework to determine near-optimal stopping boundaries is also presented. Using this framework, for a considered example, we demonstrate that a group sequential design could reduce the expected sample size under the null hypothesis by as much as 44% compared to a fixed sample approach. We conclude with a discussion of the advantages and disadvantages of the two presented procedures.

[1]  Sin-Ho Jung.  Randomized Phase II Cancer Clinical Trials , 2013 .

[2]  Boundary problem in Simon’s two-stage clinical trial designs , 2017, Journal of biopharmaceutical statistics.

[3]  James M. Robins,et al.  Semiparametric Efficiency and its Implication on the Design and Analysis of Group-Sequential Studies , 1997 .

[4]  Sin-Ho Jung,et al.  Admissible two‐stage designs for phase II cancer clinical trials , 2004, Statistics in medicine.

[5]  N. L. Johnson.  ON AN EXTENSION OF THE CONNEXION BETWEEN POISSON AND X2 DISTRIBUTIONS , 1959 .

[6]  L. Sharples,et al.  A crossover randomised controlled trial of oral mandibular advancement devices for obstructive sleep apnoea-hypopnoea (TOMADO) , 2014, Thorax.

[7]  Anastasios A. Tsiatis,et al.  Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis , 1994 .

[8]  Sample Size Calculation for Poisson Endpoint Using the Exact Distribution of Difference Between Two Poisson Random Variables , 2011 .

[9]  Paul Mathews,et al.  Sample Size Calculations: Practical Methods for Engineers and Scientists , 2010 .

[10]  Y. Takasaki.  [Continuous positive airway pressure]. , 1989, Kokyu to junkan. Respiration & circulation.

[11]  J. Wason,et al.  Optimal multistage designs for randomised clinical trials with continuous outcomes , 2011, Statistics in medicine.

[12]  Donald R Hoover,et al.  A Procedure for Group Sequential Comparative Poisson Trials , 2007, Journal of biopharmaceutical statistics.

[13]  S. Pillen,et al.  Adherence to continuous positive airway pressure in adults with an intellectual disability. , 2017, Sleep medicine.

[14]  Henry C. Thode,et al.  Power and sample size requirements for tests of differences between two Poisson rates , 1997 .

[15]  B. Turnbull,et al.  Group Sequential Methods with Applications to Clinical Trials , 1999 .

[16]  Heinz Schmidli,et al.  Group sequential designs with robust semiparametric recurrent event models , 2018, Statistical methods in medical research.

[17]  Greg Maislin,et al.  Continuous positive airway pressure treatment of sleepy patients with milder obstructive sleep apnea: results of the CPAP Apnea Trial North American Program (CATNAP) randomized clinical trial. , 2012, American journal of respiratory and critical care medicine.

[18]  Ronald R Grunstein,et al.  Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. , 2008, Proceedings of the American Thoracic Society.

[19]  A. Malhotra,et al.  Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis. , 2003 .

[20]  R J Cook,et al.  Interim monitoring of longitudinal comparative studies with recurrent event responses. , 1996, Biometrics.

[21]  J. Strackee,et al.  The frequency distribution of the difference between two Poisson variates , 1962 .

[22]  J. G. Skellam.  The frequency distribution of the difference between two Poisson variates belonging to different populations. , 1946, Journal of the Royal Statistical Society. Series A.

[23]  J. Wason,et al.  A two-stage Fisher exact test for multi-arm studies with binary outcome variables , 2017, 1711.10199.

[24]  W. Jiang.  Group sequential procedures for repeated events data with frailty. , 1999, Journal of biopharmaceutical statistics.

[25]  Adrian P Mander,et al.  Admissible two‐stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis , 2012, Pharmaceutical statistics.

[26]  Lee J. Bain,et al.  Experiment Size and Power Comparisons for Two‐Sample Poisson Tests , 1982 .

[27]  G. Elfring,et al.  Multiple-stage procedures for drug screening. , 1973, Biometrics.

[28]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[29]  G. Yi,et al.  Sequential Testing with Recurrent Events over Multiple Treatment Periods , 2010 .

[30]  Heinz Schmidli,et al.  Group sequential designs for negative binomial outcomes , 2017, Statistical methods in medical research.